Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Novartis Replaces Japan Unit Head amid SIGN Trial Probe
April 4, 2014
-
BUSINESS Independent Panel Finds Transgression of Fair Competition Code, Cover-Up over SIGN Trial
April 3, 2014
-
BUSINESS 2014 Japan Debut of Prostate Cancer Drugs to End Dearth of CRPC Treatments
April 2, 2014
-
REGULATORY Lower House Panels to Begin Deliberations on Japanese NIH-Related Bills
April 1, 2014
-
BUSINESS Torii Puts Off Launch of Sublingual Hay Fever Drug
April 1, 2014
-
BUSINESS Shionogi Predicts Milder Patent Cliff for Crestor after AZ Deal: Pres.
March 31, 2014
-
BUSINESS Suglat Tops February “Mind Share” Ranking in GP Market
March 31, 2014
-
ORGANIZATION JPMA to Ban Drug Makers from Giving Grants for Clinical Research on Own Products
March 28, 2014
-
ORGANIZATION Funding Disclosures by 5 More FPMAJ Trade Groups to Get Underway in FY2014
March 27, 2014
-
BUSINESS Major Generic Prices to Hover around 50% of Original Drug Prices in Their 1st Revision: Jiho
March 26, 2014
-
BUSINESS Novartis Will Not Sell Rasilamlo Blood Pressure Drug in Japan
March 26, 2014
-
REGULATORY MHLW to Disclose Names of Wholesalers Abusing Penalty for Low Price-Settlement Rates
March 25, 2014
-
ACADEMIA Experts Disagree over Full-Introduction of GCP at JCS Meeting
March 24, 2014
-
ORGANIZATION JPMA Urges Takeda to Improve Promotion Regime over CASE-J
March 24, 2014
-
REGULATORY MHLW to Set Rules on OTC Switching of Diagnostics This Year
March 20, 2014
-
BUSINESS Eli Lilly Japan Sales Up 9% in 2013
March 19, 2014
-
ACADEMIA Trial Investigators Brush Aside Concerns over CASE-J in US Journal
March 18, 2014
-
ACADEMIA University of Tokyo Admits Patient Information on SIGN Trial Leaked to Novartis
March 17, 2014
-
REGULATORY Eligibility for Key Pricing Premium Up for Discussion: Govt
March 17, 2014
-
BUSINESS LEO Pharma to Carefully Ponder When to Begin Solo Marketing in Japan: Local Head
March 14, 2014
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…